# Jiangsu HengRui Medicine Co., Ltd.: Phase 3 study started recruiting, 480 planned (Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. |
| NCT ID | NCT07790380 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy |
| Intervention types | drug |
| Target enrollment | 480 |
| Site countries | China |
| Posted | 2026-08-27 |
| Planned start | 2026-10-13 |
| Event | Started recruiting |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 480 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07790380). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.